Integra LifeSciences (NASDAQ: IART) reported Q1 EPS of $0.58, $0.09 better than the analyst estimate of $0.49. Revenue for the quarter came in at $357.1 million versus the consensus estimate of $349.26 million.

First Quarter 2018 Consolidated Results

• • Reported revenue was $357.1 million, an increase of 38.1% compared to the first quarter of 2017; acquisitions contributed $91.6 million of revenue to the first quarter, and organic revenues increased 3.0%;
• • GAAP earnings per share was $0.14, reflecting an increase of 75.0% compared to the first quarter of 2017;
• • Adjusted earnings per share was $0.58, reflecting an increase of 48.7% compared to the first quarter of 2017;
• • Cash flow from operations was $41.5 million, reflecting an increase of 43.8% from the first quarter of 2017;
• • The company is raising its full-year 2018 guidance based on strong first quarter results to
  • Revenue of $1.47 billion to $1.49 billion (previously $1.46 billion to $1.48 billion);
  • GAAP EPS of $0.69 to $0.77 (previously $0.60 to $0.70); and
  • Adjusted EPS of $2.34 to $2.42 (previously $2.25 to $2.35).
• • The company is reiterating its full-year 2018 guidance for organic sales growth to be approximately 5.0%.

GUIDANCE:

Integra LifeSciences sees FY2018 EPS of $2.34-$2.42, versus the consensus of $2.33. Integra LifeSciences sees FY2018 revenue of $1.47-1.49 billion, versus the consensus of $1.48 billion.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.